keyword
MENU ▼
Read by QxMD icon Read
search

Symetis

keyword
https://www.readbyqxmd.com/read/29195844/leaflet-thrombosis-following-transcatheter-aortic-valve-implantation
#1
M Marwan, N Mekkhala, M Göller, J Röther, D Bittner, A Schuhbaeck, M Hell, G Muschiol, J Kolwelter, R Feyrer, C Schlundt, S Achenbach, M Arnold
BACKGROUND: Transcatheter aortic valve implantation (TAVI) is increasingly being offered to high-risk patients with symptomatic aortic valve stenosis. Recent reports have suggested a high incidence of subclinical leaflet thrombosis following bioprosthestic aortic valve replacement. We report the frequency and clinical presentation of leaflet thrombosis identified by cardiac CT in patients referred for follow-up contrast enhanced CT angiography following TAVI. METHODS: 91 consecutive patients referred for follow-up contrast-enhanced CT angiography following TAVI were screened for inclusion in this analysis...
November 9, 2017: Journal of Cardiovascular Computed Tomography
https://www.readbyqxmd.com/read/29105687/-early-and-mid-term-results-of-the-transapical-aortic-valve-symetis-acurate-ta-a-viable-solution-in-high-risk-patients-with-severe-vascular-disease
#2
Giuseppe Rescigno, Maria Giovanna Fratesi, Carlo Aratari, Stefano Moretti, Filippo Capestro, Massimiliano Serenelli, Luca Piangerelli, Anca Delca, Gian Piero Perna, Alessandro Capucci, Marco Di Eusanio
BACKGROUND: Aortic valve stenosis is the most common valvular disease in the elderly. Transcatheter aortic valve implantation represents a viable alternative to conventional aortic valve replacement. In our Department, the transapical approach is the preferred method in patients with severe peripheral vascular disease. The aim of this study was to analyze the early and midterm results of Symetis Acurate TA implantation in our series. METHODS: From June 2013 to January 2017, 21 patients with severe peripheral vascular disease (11 male, mean age 78 ± 2...
October 2017: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/28951395/short-term-outcome-and-hemodynamic-performance-of-next-generation-self-expanding-versus-balloon-expandable-transcatheter-aortic-valves-in-patients-with-small-aortic-annulus-a-multicenter-propensity-matched-comparison
#3
Victor Mauri, Won K Kim, Mohammad Abumayyaleh, Thomas Walther, Helge Moellmann, Ulrich Schaefer, Lenard Conradi, Christian Hengstenberg, Michael Hilker, Thorsten Wahlers, Stephan Baldus, Volker Rudolph, Navid Madershahian, Tanja K Rudolph
BACKGROUND: Surgical aortic valve replacement in patients with small annular dimensions is challenging because they are at increased risk for prosthesis-patient mismatch and impaired outcomes. Transcatheter aortic valve replacement might be a good alternative; however, comparative data on different transcatheter heart valves are missing. METHODS AND RESULTS: This multicenter, propensity score-matched study compared hemodynamics and early clinical outcomes in 246 patients with an aortic annulus area <400 mm2 undergoing transcatheter aortic valve replacement with either a self-expanding transcatheter heart valve (Symetis ACURATE neo, n=129) or a balloon-expandable transcatheter heart valve (Edwards SAPIEN 3, n=117)...
October 2017: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28885378/radial-force-an-underestimated-parameter-in-oversizing-transcatheter-aortic-valve-replacement-prostheses-in-vitro-analysis-with-five-commercialized-valves
#4
Sandrine Egron, Buntaro Fujita, Lucía Gullón, Pott Désirée, Thomas Schmitz-Rode, Stephan Ensminger, Ulrich Steinseifer
The goal is to inform in depth on transcatheter aortic valve replacement (TAVR) prosthesis mechanical behavior, depending on frame type, design, and size, and how it crucially impacts the oversizing issue in clinical use, and ultimately the procedure outcome. Transcatheter aortic valve replacement is an established therapy for high-risk patients suffering from aortic stenosis, and the indication for TAVR is progressively expanding to intermediate-risk patients. Choosing the optimal oversizing degree is crucial to safely anchor the TAVR valve-which involves limiting the risks for embolism, aortic regurgitation, conductance disturbance, or annulus rupture-and to increase the valve prosthesis performance...
September 5, 2017: ASAIO Journal: a Peer-reviewed Journal of the American Society for Artificial Internal Organs
https://www.readbyqxmd.com/read/28760396/transcatheter-aortic-valve-replacement-with-new-generation-devices-a-systematic-review-and-meta-analysis
#5
Marco Barbanti, Sergio Buccheri, Josep Rodés-Cabau, Simona Gulino, Philippe Généreux, Gerlando Pilato, Danny Dvir, Andrea Picci, Giuliano Costa, Corrado Tamburino, Martin B Leon, John G Webb
OBJECTIVE: The aim of this study was to conduct a weighted meta-analysis to determine the rates of acute (≤30days) major outcomes after (TAVR) with second-generation devices. METHODS: A comprehensive search of multiple electronic databases from January 2011 to May 2017 was conducted using predefined criteria. New-generation TAVR devices were defined as any device which received CE mark approval or is still under evaluation for CE marking after CoreValve and SAPIEN XT prostheses...
October 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28655156/comparison-of-latest-generation-transfemoral-self-expandable-and-balloon-expandable-transcatheter-heart-valves
#6
Andreas Schaefer, Matthias Linder, Moritz Seiffert, Gerhard Schoen, Florian Deuschl, Niklas Schofer, Yvonne Schneeberger, Stefan Blankenberg, Hermann Reichenspurner, Ulrich Schaefer, Lenard Conradi
OBJECTIVES: We herein aimed to compare acute 30-day outcomes of latest-generation self-expandable and balloon-expandable transcatheter heart valves. METHODS: From 2012 through 2016, 104 consecutive patients (study group, 69.2% female, 81.7 ± 5.5 years, logEuroSCORE I 15.9 ± 9.3%) received transfemoral transcatheter aortic valve implantation using the Symetis ACURATE neo ® transcatheter heart valve. A control group of patients after transfemoral transcatheter aortic valve implantation with the Edwards Sapien 3™ transcatheter heart valve was retrieved from our database and matched to the study group...
June 26, 2017: Interactive Cardiovascular and Thoracic Surgery
https://www.readbyqxmd.com/read/28544829/symetis-tf-acurateneo%C3%A2-valve-in-valve-a-new-indication-for-another-self-expanding-tavi-prosthesis
#7
Elton Pllaha, Paolo Pagnotta, Marco Rossi, Bernhard Reimers
During the past decade there has been a major shift in the use of surgical bioprostheses. Consequently, due to the increasing age of the population there will be a major increase in the incidence of failure of these prostheses. While mortality associated with the re-replacement of surgical valve failures remains high, advances in transcatheter interventions have permitted the use of transcatheter valves in degenerative surgical bioprostheses. Herein is described the first use of the Symetis transfemoral ACURATEneo™ valve-in-valve procedure, together with details of the associated technical challenges...
January 2017: Journal of Heart Valve Disease
https://www.readbyqxmd.com/read/28296065/direct-percutaneous-transaxillary-implantation-of-a-novel-self-expandable-transcatheter-heart-valve-for-aortic-stenosis
#8
Florian Deuschl, Niklas Schofer, Moritz Seiffert, Samer Hakmi, Isamu Mizote, Andreas Schaefer, Johannes Schirmer, Hermann Reichenspurner, Stefan Blankenberg, Lenard Conradi, Ulrich Schäfer
OBJECTIVES: The aim of this study was to evaluate safety, feasibility, and efficacy of transaxillary TAVI using a novel self-expandable transcatheter heart valve (THV) via a direct percutaneous technique. METHODS: The analysis comprises 12 consecutive patients with severe aortic stenosis treated with the ACURATE Neo™ THV (Symetis) by direct percutaneous transaxillary access. RESULTS: Patients presented with a mean age of 79.9 ± 6.2 years and high calculated surgical risk (logEuroSCORE I: 19...
March 15, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28073571/early-clinical-outcomes-of-a-novel-self-expanding-transapical-transcatheter-aortic-valve-bioprosthesis
#9
Michael W A Chu, Rodrigo Bagur, Katie L Losenno, Philip M Jones, Pantelis Diamantouros, Patrick Teefy, Jill J Gelinas, Bob Kiaii
OBJECTIVE: Coronary obstruction remains a challenging complication of transcatheter aortic valve replacement; however, a new self-expanding transapical prosthesis may reduce this risk. The purpose of this study was to evaluate the early 1-year outcomes of patients with low coronary heights who received the Acurate TA bioprosthesis (Symetis, Ecublens, Switzerland). METHODS: Between May 2014 and April 2015, 30 consecutive patients (aged 85 ± 6 years, 63% were female, Society of Thoracic Surgeons score 8...
April 2017: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/27872440/successful-percutaneous-implantation-of-symetis-acurate-neo-transcatheter-aortic-bioprosthesis-in-a-patient-with-existing-mechanical-mitral-valve
#10
Sina Ali, Yakup Alsancak, Mustafa Duran, Mehmet Bilge
No abstract text is available yet for this article.
November 2016: Anatolian Journal of Cardiology
https://www.readbyqxmd.com/read/27677241/first-north-american-experience-with-the-transfemoral-acurate-neo-tm-self-expanding-transcatheter-aortic-bioprosthesis
#11
Rodrigo Bagur, Patrick J Teefy, Bob Kiaii, Pantelis Diamantouros, Michael W A Chu
BACKGROUND: Transcatheter aortic valve implantation (TAVI) has become a therapeutic alternative for patients presenting with severe symptomatic aortic stenosis and considered at high-surgical risk. Paravalvular leak (PVL), conduction disorders, and coronary obstruction remain unresolved procedure-related complications. The aim of this manuscript was to report the first North American experience with the ACURATE-neo(TM) aortic bioprosthesis and its ACURATE-TF(TM) delivery system (Symetis S...
July 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/26888463/improving-outcomes-case-matched-comparison-of-novel-second-generation-versus-first-generation-self-expandable-transcatheter-heart-valves
#12
Andreas Schaefer, Hendrik Treede, Gerhard Schoen, Florian Deuschl, Niklas Schofer, Yvonne Schneeberger, Stefan Blankenberg, Hermann Reichenspurner, Ulrich Schaefer, Lenard Conradi
OBJECTIVES: The published literature has extensively documented clinical benefit derived from transcatheter aortic valve implantation (TAVI) in high-risk patients using self-expanding current-generation transfemoral (TF) transcatheter heart valves (THVs). However, it has also demonstrated apparent shortcomings such as paravalvular leakage (PVL) or need for permanent pacemaker (PM) implantation. We here present a case-matched analysis of acute 30-day outcomes using a novel nitinol-based THV (Symetis Acurate Neo TF™), which may overcome some limitations of currently used devices...
August 2016: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/26762474/successful-percutaneous-implantation-of-symetis-acurate-neo-transcatheter-aortic-bioprosthesis-for-the-treatment-of-pure-aortic-regurgitation
#13
Alfredo Giuseppe Cerillo, Daniel Griese, Sergio Berti
Transcatheter aortic valve implantation (TAVI) was initially developed for the treatment of calcific aortic stenosis. In the recent years, however, TAVI has been used to treat selected patients with pure, severe AR. We report successful transfemoral implantation of a Symetis ACURATE neo bioprosthesis in a severely symptomatic, 87-year-old woman with pure AR and major comorbidities. We decided to use the ACURATE neo bioprosthesis for some of its features appeared to us as potentially useful in the setting of pure AR: the stabilization arches ensure perfect coaxial alignment and extreme stability of the device during deployment, and the "waist" and the skirt were considered useful to obtain a good seal in the absence of significant valvular and annular calcifications...
August 2016: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/26522576/transcatheter-acurate-ta-aortic-valve-implantation-in-a-patient-with-a-previous-mechanical-mitral-valve
#14
Rodrigo Bagur, Bob Kiaii, Patrick J Teefy, Pantelis Diamantouros, Christopher Harle, Aashish Goela, Ian Chan, Michael W A Chu
Transcatheter aortic valve implantation (TAVI) in the presence of a mechanical mitral valve (MMV) prosthesis is still challenging because of the rigid mitral frame within the aortomitral curtain. Moreover, low-lying coronary ostia represent a hazardous problem of coronary obstruction, especially in narrow or porcelain aortic roots. The present case demonstrates the successful management of 2 challenging anatomical issues, the rigid cage of the MMV and the low-lying left main coronary ostium (LMCO), with the implantation of the ACURATE-TA bioprosthesis (Symetis SA, Ecublens, Switzerland)...
November 2015: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/26198875/symetis-acurate-tavi-review-of-the-technology-developments-and-current-data-with-this-self-expanding-transcatheter-heart-valve
#15
REVIEW
U Schäfer, L Conradi, P Diemert, F Deuschl, N Schofer, M Seiffert, E Lubos, J Schirmer, H Reichenspurner, S Blankenberg, H Treede
The Symetis ACURATE TA and ACURATE neo technology is a novel transcatheter heart valve for treatment of aortic valvular stenosis. This review illustrates the implantation steps, which are designed for an easy and intuitive transapical and transfemoral TAVI procedure. The most important difference to other self-expanding platforms is the top-down deployment with minimal protrusion of the stent towards the left ventricular outflow tract. In addition, the supra-annularly placed porcine leaflets provide very low gradients and the pericardial skirt acts very effectively to seal against paravalvular leaks...
October 2015: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/26160399/device-landing-zone-calcification-and-its-impact-on-residual-regurgitation-after-transcatheter-aortic-valve-implantation-with-different-devices
#16
MULTICENTER STUDY
Moritz Seiffert, Buntaro Fujita, Maxim Avanesov, Clemens Lunau, Gerhard Schön, Lenard Conradi, Emir Prashovikj, Smita Scholtz, Jochen Börgermann, Werner Scholtz, Ulrich Schäfer, Gunnar Lund, Stephan Ensminger, Hendrik Treede
AIMS: Calcification of the device landing zone is linked to paravalvular regurgitation after transcatheter aortic valve implantation (TAVI). The mechanisms remain incompletely understood and the performance of next-generation transcatheter heart valves (THV) has not been investigated. We evaluated the impact of calcification patterns on residual aortic regurgitation (AR) after TAVI with different THV in patients with severe aortic stenosis. METHODS AND RESULTS: TAVI was performed in 537 patients at two centres...
May 2016: European Heart Journal Cardiovascular Imaging
https://www.readbyqxmd.com/read/25841857/symetis-valve-implantation-in-failing-freestyle-with-close-proximity-between-coronary-ostia-and-annulus
#17
Jeevan Nagendran, Jorge Catrip, Pantelis Diamantouros, Patrick Teefy, Bob Kiaii, Ian Chan, Aashish Goela, David M Holzhey, Michael W A Chu
Transcatheter treatment of patients with degenerated aortic valve stentless prosthesis and low proximal coronary ostia to the aortic annulus remain a challenge because of the elevated risk for coronary obstruction. Newer generation transcatheter aortic valve devices that engage and pull the aortic valve calcium towards the aortic annulus may be beneficial in these patients. We present a case of successful treatment of a degenerated tubular stentless prosthesis with low coronary ostia with a Symetis Acurate TA prosthesis...
April 2015: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/25720330/challenges-of-coronary-angiography-and-intervention-in-patients-previously-treated-by-tavi
#18
COMPARATIVE STUDY
Johannes Blumenstein, Won-Keun Kim, Christoph Liebetrau, Luise Gaede, Joerg Kempfert, Thomas Walther, Christian Hamm, Helge Möllmann
OBJECTIVE: Since the beginning of the transcatheter aortic valve implantation (TAVI) era, many prosthetic valves have entered clinical practice. TAVI prostheses differ regarding stent design and some may potentially interfere with diagnostic or interventional catheters. The aim of our analysis was to evaluate the feasibility of coronary angiography (CA) or percutaneous coronary intervention (PCI) in patients with prior TAVI. METHODS: From 2011 to 2014, 1,000 patients were treated by TAVI at our center using eight different valve prostheses (Symetis ACURATE TA and ACURATE TF; Medtronic CoreValve and Engager; JenaValve, SJM Portico; Edwards Lifesciences SAPIEN and SAPIEN XT)...
August 2015: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/25661576/single-institution-experience-with-transcatheter-valve-in-valve-implantation-emphasizing-strategies-for-coronary-protection
#19
Daniele Camboni, Andreas Holzamer, Bernhard Flörchinger, Kurt Debl, Dierk Endeman, York Zausig, Lars S Maier, Christof Schmid, Michael Hilker
BACKGROUND: Transcatheter valve-in-valve (VIV) implantation evolved as a therapeutic alternative, despite an increased risk of coronary obstruction in comparison with a regular transcatheter aortic valve implantation (TAVI). We report a comprehensive single-institution experience emphasizing strategies to reduce the risk of myocardial ischemia. METHODS: Since 2009, 639 patients underwent a TAVI procedure in our institution. All patients are prospectively collected into an institutional registry...
May 2015: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/25425552/first-registry-results-from-the-newly-approved-acurate-ta%C3%A2-tavi-system%C3%A2
#20
MULTICENTER STUDY
Jörg Kempfert, David Holzhey, Steffen Hofmann, Evaldas Girdauskas, Hendrik Treede, Holger Schröfel, Matthias Thielmann, Thomas Walther
OBJECTIVES: The novel ACURATE TA™ transcatheter aortic valve (Symetis, Ecublens, Switzerland) is composed of a self-expanding nitinol stent covered by an anti-paravalvular leak skirt designed for transapical implantation. Since Conformite Europeenne (CE)-mark approval, the first 250 patients implanted with the newly approved device have been included in this post-market, multicentre registry. METHODS: The registry was conducted at 17 sites in Germany, Italy, Switzerland and Argentina to treat 250 high-risk elderly patients...
July 2015: European Journal of Cardio-thoracic Surgery
keyword
keyword
49673
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"